Revenue Increased 19% both Sequentially and Year over Year
Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of
Year Over Year Improvement Due to Successful Cost Cutting Initiatives
Management to Host Conference Call Today at 5:00 pm ET
LITTLETON, Colo., August 14, 2024 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and…
